These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 14530872

  • 1. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
    Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E.
    Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
    [Abstract] [Full Text] [Related]

  • 2. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
    Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J.
    Bone Marrow Transplant; 2000 Jul; 26(2):141-5. PubMed ID: 10918423
    [Abstract] [Full Text] [Related]

  • 3. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG.
    Blood; 1997 May 01; 89(9):3118-28. PubMed ID: 9129014
    [Abstract] [Full Text] [Related]

  • 4. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
    Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK.
    Exp Hematol; 2002 Sep 01; 30(9):1044-50. PubMed ID: 12225796
    [Abstract] [Full Text] [Related]

  • 5. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
    Basser RL.
    Stem Cells; 1998 Sep 01; 16 Suppl 2():225-9. PubMed ID: 11012194
    [Abstract] [Full Text] [Related]

  • 6. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
    Sheridan W, Menchaca D.
    Stem Cells; 1998 Sep 01; 16 Suppl 2():193-8. PubMed ID: 11012191
    [Abstract] [Full Text] [Related]

  • 7. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
    Kabaya K, Shibuya K, Torii Y, Nitta Y, Ida M, Akahori H, Kato T, Kusaka M, Miyazaki H.
    Bone Marrow Transplant; 1996 Dec 01; 18(6):1035-41. PubMed ID: 8971370
    [Abstract] [Full Text] [Related]

  • 8. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
    Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D.
    Blood; 1999 Dec 01; 94(11):3694-701. PubMed ID: 10572081
    [Abstract] [Full Text] [Related]

  • 9. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.
    Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, Menchaca D, Tomita D, Ozer H, Harker L.
    N Engl J Med; 1997 Feb 06; 336(6):404-9. PubMed ID: 9010146
    [Abstract] [Full Text] [Related]

  • 10. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.
    Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM.
    Blood; 2000 Apr 15; 95(8):2530-5. PubMed ID: 10753831
    [Abstract] [Full Text] [Related]

  • 11. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis.
    Ide Y, Harada K, Imai A, Yanagida M.
    Int J Hematol; 1999 Aug 15; 70(2):91-6. PubMed ID: 10497847
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
    Farese AM, MacVittie TJ, Roskos L, Stead RB.
    Stem Cells; 2003 Aug 15; 21(1):79-89. PubMed ID: 12529554
    [Abstract] [Full Text] [Related]

  • 15. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
    Kabaya K, Akahori H, Shibuya K, Nitta Y, Ida M, Kusaka M, Kato T, Miyazaki H.
    Stem Cells; 1996 Nov 15; 14(6):651-60. PubMed ID: 8948023
    [Abstract] [Full Text] [Related]

  • 16. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
    Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG.
    Lancet; 1996 Nov 09; 348(9037):1279-81. PubMed ID: 8909381
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
    Molineux G, Hartley C, McElroy P, McCrea C, Kerzic P, McNiece I.
    Stem Cells; 1997 Nov 09; 15(1):43-9. PubMed ID: 9007221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.